Moreover, TGF-β could increase the cancer stem cell (CSC) population in a Smad4-dependent manner from clinical and preclinical data, and TGF-β signaling enhances tumor recurrence through interleukin (IL)−8-dependent expansion of CSCs in triple-negative breast cancer12. Here, SMAD4 is linked to cancer.